Protocol Ledger

NCT03512314 · Phase III · COMPLETED

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension

Interventional Phase III clinical trial protocol NCT03512314 sponsored by AB2 Bio in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-01-24 Enrollment: 11 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03512314
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)11 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03512314
Protocol FieldVerified Registry Value
NCT IdentifierNCT03512314
Consolidated Lead SponsorAB2 Bio
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment11 participants (ACTUAL)
Registered Start Date2018-01-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI